ストックスクリーナーアプリを入手
1.41
1.44%
0.02
前日終値:
$1.39
開ける：
$1.38
24時間の取引高:
375.17K
Relative Volume:
0.37
時価総額：
$66.00M
収益：
当期純損益:
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
1週間 パフォーマンス:
-12.96%
1か月 パフォーマンス:
-20.79%
6か月 パフォーマンス:
+2.17%
1年 パフォーマンス:
-27.69%
1日の値動き範囲:
$0.00
$0.00
1週間の範囲:
$1.375
$1.66
52週間の値動き範囲:
$1.15
$2.25
OS Therapies Incorporated Stock (OSTX) Company Profile
Compare OSTX vs VRTX, MRNA, REGN, ARGX, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OSTX
OS Therapies Incorporated
|
1.41 | 66.00M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
OS Therapies Incorporated Stock (OSTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-07-09 | 開始されました | Roth Capital | Buy |
| 2025-04-02 | 開始されました | Lake Street | Buy |
OS Therapies Incorporated (OSTX) 最新ニュース
OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History - Yahoo Finance
Rubenstein Public Relations Named Agency of Record for OS Therapies - Yahoo Finance
A dog cancer treatment could launch in the U.S. in 2027, OS Therapies hopes - Stock Titan
OSTX Stock Holds Tight Range As Traders Probe Weak Financials - StocksToTrade
OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial - marketscreener.com
72.7% of treated patients survived three years, versus 45.8% in historical comparisons. - stocktitan.net
Os Therapies Incorporated (OSTX-A) Stock Price and News - The Globe and Mail
OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer - marketscreener.com
OS Therapies has received over $3M in tax refunds and accrued over $7M in research tax credits. - Stock Titan
OS Therapies Incorporated (OSTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) - Yahoo Finance
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Axalta Coating Systems (AXTA) - The Globe and Mail
OS Therapies (OSTX) Slips to $1.75 as Shares Sit Between Key LevelsHedge Fund Favorites - dars.gov.et
OS Therapies (OSTX) Slips to $1.75 as Shares Sit Between Key LevelsLeveraged ETF Flow - siam.in
The FDA has approved 29 U.K.-led cancer drugs since 2021. Now a U.K. regulator will lead OS Therapies’ review. - Stock Titan
OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis - Yahoo Finance
OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program - Yahoo Finance
Analysts Offer Insights on NA Companies: Waystar Holding Corp. (WAY) and OS Therapies Incorporated (OSTX) - The Globe and Mail
A bone cancer treatment gets UK regulator agreement. OS Therapies plans its next trial. - Stock Titan
OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing - Yahoo Finance
Form 8K OS Therapies Inc For: 10 September By Investing.com - Investing.com UK
Analysts’ Top NA Picks: BioAge Labs, Inc. (BIOA), OS Therapies Incorporated (OSTX) - The Globe and Mail
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Concentra Group Holdings Parent, Inc. (CON) - The Globe and Mail
An interim cancer-trial analysis found 71.2% three-year survival versus 45.8% in a historical group. - Stock Titan
OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial - Yahoo Finance
OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance - Yahoo Finance
Analysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Nicola Mining Inc. Unsponsored ADR (NICM) - The Globe and Mail
OS (OSTX) End-of-Day Review: Ends Lower by 2.04% at $1.44 for the Current Session; Level Position: the Price Remains Bounded by the Supplied Support and Resistance at the CloseFlat Correction - careplusvn.com
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates - newsfilecorp.com
OS Therapies Expects 3-Year Survival Data in September - Stock Titan
OS Therapies (OSTX) Edges Lower to $1.6, Holding Above Key SupportDividend Arbitrage - careplusvn.com
OS Therapies Incorporated Revenue Breakdown – AMEX:OSTX - TradingView
OS Therapies Incorporated (OSTX) Q1 2026 Earnings: Wider-Than-Expected Loss Highlights Cash Burn and Pre-Revenue StageROA Comparison - dars.gov.et
OS Therapies (OSTX) Faces Continued Pressure as Shares Test Key SupportETF Creation Redemption - dars.gov.et
Roth MKM Initiates a Buy Rating on OS Therapies Incorporated (OSTX) - The Globe and Mail
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program - Yahoo Finance
OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street - The Globe and Mail
OS Therapies Incorporated (OSTX) Gets a Buy from Lake Street - The Globe and Mail
OS Therapies Third Quarter 2026 Corporate Outlook - Yahoo Finance
OS Therapies Provides U.S. Regulatory Update - Yahoo Finance
OS Therapies Incorporated(NYSEAM:OSTX) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma - Yahoo Finance
OS Therapies Releases Q1 2026 Financial Results - AlphaStreet
EDGAR Filing Documents for 0001213900-26-050211 - SEC.gov
OS Therapies Investor News: Rosen Law Firm Encourages OS Therapies Incorporated Investors to Inquire About Securities Class Action Investigation – OSTX - Business Wire
Cancer drug developer taps Guardant executive for regulator strategy - Stock Titan
OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors - Yahoo Finance
OS Therapies Incorporated (OSTX) stock price, news, quote and history - Yahoo Finance UK
OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting - Yahoo Finance
OS Therapies Incorporated (OSTX) 財務データ
OS Therapies Incorporated (OSTX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
1.35%
大文字化:
|
ボリューム (24 時間):